Skip to main content
Premium Trial:

Request an Annual Quote

Celmatix Receives NY State Approval for Reproductive Health Gene Panel

NEW YORK (GenomeWeb) – Celmatix's multi-gene panel test for reproductive health conditions, Fertilome, has been approved by New York State's Department of Health as a laboratory-developed test, the firm said today.

Fertilome is a blood-based assay that analyzes 49 DNA variants in 32 genes that are associated with women's reproductive health conditions, such as endometriosis, polycystic ovarian syndrome, recurrent pregnancy loss, and early menopause. The company launched the test from its CLIA-certified laboratory in New York in January through a pre-approval program administered by the state.

"The stringent criteria for approval in New York State serves as a guidepost for clinical laboratories across the country, and having achieved this approval is a strong validation of the science and methodology behind our groundbreaking test," Lesley Northrop, clinical laboratory director of Celmatix Clinical Laboratories, said in a statement.

Celmatix CEO Piraye Yurttas Beim said that the firm wanted to launch the test in New York, which has stringent requirements for LDTs, in order to demonstrate that it had both clinical validity and clinical utility. "We are very sensitive to the emotional and financial burdens on women considering egg freezing or undergoing fertility treatments," Beim added.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.